1.      Amin S, Levy CF. Rhabdomyosarcoma and other soft-tissue sarcomas. In: Fish JD, Lipton JM, Lanzkowsky P, eds. Lanzkowsky’s Manual of Pediatric Hematology and Oncology. 7th ed. Oxford: Elsevier; 2022:541-561.

2.      Crane JN,Xue W, Qumseya A, et al. Clinical group and modified TNM stage for rhabdomyosarkma: A review from the Children’s Oncology Group. Pediatr Blood Cancer.2022; 69:e29644 doi: 10.1002/pbc.29644.

3.      Joshi D, Anderson JR, Paidas C, et al. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children’s Oncology Group. Pediatr Blood Cancer. 2004;42:64-73.

4.      Lawrence WJ, Anderson JR, Gehan EA, et al. Pretreatment TNM staging of childhood rhabdomyosarcoma: a report of the Intergroup Rhabdomyosarcoma Study Group. Cancer. 1997;80:1165-1170.Linardic CM, Wexler LH. Rhabdomyosarcoma. In: Pizzo PA, Poplack DG, eds. Pizzo and Poplack’s Pediatric Oncology. 8th ed. Philadelphia: Wolters Kluwer; 2021:693-720.

5.      Malempati S, Rodeberg DA, Donaldson SS, et al. Rhabdomyosarcoma in infants younger than 1 year: a report from the Children’s Oncology Group. Cancer. 2011;117:3493-3501.

6.      Million L, Donaldson SS. Advances in radiotherapy for pediatric soft tissue sarcomas. Curr Opin Pediatr. 2010;22:17-24.

7.      Oberlin O, Rey A, Lyden E, et al. Prognostic factors in metastatic rhabdomyosarcomas. J Clin Oncol. 2008;26:2384-2389.

8.      Rodeberg DA, Garcia-Henriquez N, Lyden ER, et al. Prognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol. 2011;29:1304-1311.

9.      SIOP Clinical Practicce Guidelines for patients with rhabdomyosarcoma. Document version 1.6 05.02.2022

10.  Skapek SX, Anderson J, Barr FG, et al. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a Children’s Oncology Group report. Pediatr Blood Cancer. 2013;60:1411-1417.

11.  Spunt. SI., Million L., Chi YY .2020 A risk based treatment strategy for non-rhabdomyosarkoma soft tissue sarcomas in patients younger than 30 years (ARST0332): Children’s Oncology Group prospective study. Lancet Oncol 21, 145-161.

12.  Weiss AR, Lyden ER, Anderson JR, et al. Histologic and clinical characteristics can guide staging evaluations for children and adolescents with rhabdomyosarcoma: a report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. J Clin Oncol. 2013;31:3226-3232.